Metsera - About the company
Metsera is an acquired company based in New York City (United States), founded in 2022. It operates as a Biopharmaceutical company focusing on medicines for obesity and metabolic diseases. Metsera has raised $505M in funding from investors like Venrock, Arch Venture Partners and Wellington, with last known valuation of $*****. The company has 72 active competitors, including 35 funded and 16 that have exited. Its top competitors include companies like Adaptive Biotechnologies, Adocia and Fractyl.
Company Details
Biopharmaceutical company focusing on medicines for obesity and metabolic diseases. The company's portfolio unlock new treatment strategies through scalable, sustainable and personalized interventions for weight loss, weight maintenance and disease prevention.
- Website
- metsera.com
- Email ID
- *****@metsera.com
Key Metrics
Founded Year
2022
Location
New York City, United States
Stage
Acquired
Total Funding
$505M in 2 rounds
Latest Funding Round
Last Known Valuation
$***** as on Apr 03, 2026
Ranked
10th among 72 active competitors
Employee Count
75 as on Apr 30, 2026
Exit Details
Acquired by Pfizer (Sep 22, 2025)
Legal entities associated with Metsera
Metsera is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
METSERA, INC. CIN: 6825593 , United States, Active | May 05, 2023 | - | - | - |
Metsera's acquisition details
Click here to take a look at Metsera's acquisition in detail
Sign up to download Metsera's company profile
Metsera's funding and investors
Metsera has raised a total funding of $505M over 2 rounds. Its first funding round was on Apr 18, 2024. Its latest funding round was a Series B round on Nov 12, 2024 for $*****. 14 investors participated in its latest round. Metsera has 16 institutional investors.
Here is the list of recent funding rounds of Metsera:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 12, 2024 | 8747020 | Series B | 7960305 | 8590966 | 3560742 | 7842774 |
Apr 18, 2024 | 7843600 | Series A | 4615198 | 4853727 |
Access funding benchmarks and valuations. Sign up today!View details of Metsera's funding rounds and investors
Metsera's founders and board of directors
Founder? Claim ProfileMetsera's employee count trend
Metsera has 75 employees as of Apr 26. Here is Metsera's employee count trend over the years:
Uncover Metsera's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Metsera's Competitors and alternates
Top competitors of Metsera include Adaptive Biotechnologies, Adocia and Fractyl. Here is the list of Top 10 competitors of Metsera, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Adaptive Biotechnologies 2009, Seattle (United States), Public | Provider of clinical diagnostics, and drug discovery for immune diseases | $419M | 73/100 | |
2nd | Developer of therapeutics for the treatment of diabetes and obesity | $26M | 69/100 | ||
3rd | Fractyl 2010, Lexington (United States), Public | Provider of Endoscopic procedure for type - 2 diabetes | $345M | 67/100 | |
4th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
5th |  Enveda 2019, Boulder (United States), Series D | AI-based platform to decipher the chemistry of nature and develop new medicines | $517M | 63/100 | |
6th | Kailera 2024, Waltham (United States), Series B | Developer of therapies for treating obesity and related conditions | $1B | 62/100 | |
7th |  D&D Pharmatech 2018, Seongnam-si (South Korea), Public | Developer of small molecule based therapeutics for the treatment of CNS diseases | $205M | 62/100 | |
8th |  MBX Biosciences 2018, Carmel (United States), Public | Developer of drugs for the treatment of rare endocrine diseases | $216M | 61/100 | |
9th |  Congruence Therapeutics 2021, Montreal (Canada), Series B | Developer of therapeutics for the treatment of rare diseases | $97M | 61/100 | |
10th |  Metsera 2022, New York City (United States), Acquired | Biopharmaceutical company focusing on medicines for obesity and metabolic diseases | $505M | 61/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Metsera's competitors? Click here to see the top ones
Metsera's Investments and acquisitions
Metsera has made no investments or acquisitions yet.
Reports related to Metsera
Here is the latest report on Metsera's sector:
News related to Metsera
Filter this listMedia has covered Metsera for a total of 56 events in the last 1 year, 17 of them have been about company updates.
•
Pfizer agrees to acquire Metzela for over $10 billionThe Wall Street Journal•Mar 09, 2026•Pfizer, Metsera, IP Group
•
Pfizer Completes Acquisition of Metsera for $7 Billion Plus Contingent Value RightMedical Dialogues•Nov 16, 2025•Metsera, Pfizer
•
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In IndiaBenzinga•Nov 12, 2025•Metsera, Novo Nordisk, Pfizer, Midwesttrust
•
Johnson Fistel Investigates Fairness of Proposed Metsera Sale to PfizerBenzinga•Nov 12, 2025•Johnson Fistel, Metsera, Pfizer
•
Pfizer Announces Acquisition Deal of Metsera for $5.5 Billionnovini247.com•Nov 10, 2025•Metsera, Novo Nordisk, Pfizer
•
Metsera accepts $10 billion takeover offer from PfizerBoursier.com•Nov 08, 2025•Metsera, Pfizer, Novo Nordisk
•
•
Novo Nordisk Will Not Increase Its Proposal to Acquire MetseraGlobeNewswire•Nov 08, 2025•Metsera, Novo Nordisk, Pfizer
•
FTC Raises Concerns About Structure of Novo Nordisk's Bid for MetseraEndpoints•Nov 06, 2025•Metsera, Novo Nordisk
•
Metsera Receives Amended Proposal from Novo Nordisk Valued at $10 BillionPR Newswire•Nov 04, 2025•Metsera, Novo Nordisk, Pfizer, Team Novo Nordisk
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Metsera
Explore our recently published companies
- City Watch - Nigeria based, 2007 founded, Unfunded company
- AEXLAB - Phoenix based, 2015 founded, Series A company
- Newsreel - United States based, 2019 founded, Unfunded company
- Peni Ice Candy - Ernakulam based, 1997 founded, Unfunded company
- Formula Student Germany - Bad Abbach based, 2017 founded, Unfunded company
- OzaBio - Wilmington based, 2022 founded, Unfunded company
